Letters, Testimony & Comments

BIO submits letters, testimony, and comments to government and regulatory bodies throughout the United States and around the world.

Featured Letters, Testimony, & Comments
BIO Response to Senate Finance Committee Minority…
BIO Letter on AR HB1531
BIO Comments to Pharmacy Compounding Advisory…
All Letters, Testimony & Comments
  • Show All
Search
Results
January 26, 2016
Food and Drug Administration Docket No. FDA-2015-D-4272; Food Labeling; Voluntary Labeling Indicating Whether Food Has or Has Not Been Derived From Genetically Engineered Atlantic Salmon; Draft Guidance for Industry.
October 30, 2015
As you finalize the proposed rules under the Renewable Fuel Standard, we respectfully urge you to not reduce the biofuels volume requirements. The RFS program has helped the environment, our economy, and has increased our confidence in renewable…
October 22, 2015
RE: Docket No. FDA–2015–D–2818 Draft Guidance for Industry: Rare Diseases—Common Issues in Drug Development Dear Sir/Madam: The Biotechnology Industry Organization (BIO) appreciates the opportunity to provide feedback in response to the…
March 9, 2014
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments to the docket regarding “Complex Issues in Developing Drug and Biologics Products for Rare Diseases.” Comments are…
May 31, 2010
BIO’s final comments on Considerations Regarding Food and Drug Administration Review and Regulation of Articles for the Treatment of Rare Diseases.